Enphase Energy Inc vs McKesson Corporation — how do they compare? Enphase Energy Inc trades at $32.7 (market cap $4.35B), while McKesson Corporation trades at $941.25 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 24.9× Enphase Energy Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and McKesson Corporation for 74 Days on average.
| ENPH | MCK | |
|---|---|---|
Market Cap | $4.35B | $108.46B |
Volume | 5,068,595 | 712,607 |
Sector | Energy | Health |
52-Week High | $72.33 | $995.69 |
52-Week Low | $26.12 | $725.17 |
Typical Hold Time | 72 Days | 74 Days |
Enterprise Value | $3.99B | $115.00B |
Dividend Yield | — | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.095, down 4.19% with bearish technical signals. The stock shows mixed fundamentals with revenue declining from $2.3B in 2023 to $1.47B in 2025, though net income margin improved to 11.68%. Recent earnings show two misses in the last three quarters. Analyst sentiment is divided with 42% buy ratings but a consensus price target of $42.90 suggesting 34% upside. The company continues innovation with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
The stock faces headwinds from solar industry pressures and elevated borrowing costs, but maintains strong gross margins and product innovation. With current price near support at $32 and significant upside to analyst targets, ENPH presents a contrarian opportunity for investors believing in the long-term solar growth story despite near-term volatility.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →